GlassScriptPhysician profile
Jacquelyn Oliai
NPI 1306099973
$4,071.93
in general payments reported to CMS, 2019-2025
27 companies · $854 in 2025
The $854 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.33 · 2022: $901 · 2023: $1,215 · 2024: $1,091 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,159.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,723.92 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Mitraclip |
| Medtronic, INC. | $278.41 | 2024-2025 | Symplicity G3, Venaseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.50 | 2022-2024 | Jardiance |
| Pfizer INC. | $194.92 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $171.84 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $158.86 | 2023-2024 | Camzyos |
| Gilead Sciences, INC. | $157.18 | 2024-2025 | Epclusa, Livdelzi |
| Insulet Corporation | $129.09 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2024 | Rexulti |
| One Lambda, INC. | $110.39 | 2024 | |
| Boston Scientific Corporation | $84.35 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.79 | 2024 | Lifevest |
| Idorsia Pharmaceuticals US INC | $74.55 | 2023 | Quviviq |
| Viatris Specialty LLC | $70.32 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $66.62 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $61.75 | 2024 | |
| Amgen INC. | $60.58 | 2022 | |
| Acadia Pharmaceuticals INC | $54.59 | 2024 | Nuplazid |
| Novo Nordisk INC | $38.72 | 2022 | |
| Abbvie INC. | $34.50 | 2023 | |
| Lundbeck LLC | $32.09 | 2022 | |
| Biogen, INC. | $26.25 | 2025 | Skyclarys |
| Genentech USA, INC. | $26.06 | 2023 | Tecentriq |
| Daiichi Sankyo INC. | $23.30 | 2022 | |
| Grifols USA, LLC | $20.32 | 2023 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $14.37 | 2022 | |
| Merck Sharp & Dohme LLC | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Oliai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.